What Is Akeega (Niraparib/Abiraterone)? FDA Approval, Licensing in Türkiye, and Reimbursement Status
In this article
Precision Medicine in Prostate Cancer: Akeega (Niraparib/Abiraterone)
The era of genetic profiling in prostate cancer treatment has entered a new phase with Akeega® . Particularly in metastatic prostate cancer with a BRCA2 mutation, this combination targets both hormonal pathways and DNA repair mechanisms, producing groundbreaking survival results.
Drug Profile
- Brand Name: Akeega®
- Active Ingredients: Niraparib + Abiraterone Acetate
- Class: PARP Inhibitor + CYP17 Inhibitor Combination
- Administration: Oral (tablet taken by mouth)
- Manufacturer: Janssen (Johnson & Johnson)
- Licensing: The licensing process in Türkiye is ongoing (available through early-access programs).
- Reimbursement: It is not yet on the general SGK reimbursement list (SUT).
- Access: Eligible patients with a detected BRCA mutation may access it through individual treatment (prescription-based import from abroad) or clinical trials. The average overseas price is €6,200 - €6,800.
Approved Indications
- Metastatic Castration-Resistant Prostate Cancer (mCRPC): In adults with a BRCA mutation (germline and/or somatic) detected by an FDA-approved test.
- [NEW - JANUARY 2026] Metastatic Castration-Sensitive Prostate Cancer (mCSPC): In patients with a BRCA2 mutation in the early metastatic stage who have not yet developed hormonal resistance.
FDA Approval History
Akeega has demonstrated its "smart bomb" effect by combining a PARP inhibitor with hormonal treatment:
The FDA approved Akeega based on MAGNITUDE for BRCA-positive metastatic castration-resistant patients. It became the world's first and only dual-action prostate cancer tablet.
Long-term follow-up of clinical data showed that, in patients with a BRCA2 mutation, starting treatment before resistance develops (at the mCSPC stage) improved radiographic progression-free survival (rPFS) by over 40%, expanding the approval.
What Is Akeega, and What Is Its Molecular Mechanism?
Akeega surrounds the cancer cell at two vital points through the principles of "synthetic lethality" and "androgen deprivation" .
🔬 A Dual Attack at the Molecular Level
- 1. Blocking the DNA Repair Pathway (Niraparib):
DNA in BRCA-mutated cells is already damaged. By inhibiting PARP, niraparib closes the cell's remaining DNA repair pathways. Irreparable DNA damage causes cancer-cell suicide (apoptosis). - 2. Cutting Off the Fuel Supply (Abiraterone):
Prostate cancer cells need testosterone to grow. Abiraterone blocks CYP17, reducing the body's testosterone production—including in the adrenal glands and tumor itself—to near-zero levels. - 3. Synergistic Power:
Suppressing hormone receptors makes cells more sensitive to PARP inhibitors. This dual effect creates much stronger antitumor activity than either used alone.
Administration and Dosage
Akeega comes as a single tablet formulation to improve adherence and requires a daily routine. 1 Akeega tablet contains 100 mg niraparib + 500 mg abiraterone acetate.
- Standard Dose: The usual dose is 2 tablets taken together once daily (each tablet contains 100 mg niraparib / 500 mg abiraterone).
- Concomitant Treatment: Akeega must be taken with 5 mg twice daily of prednisone (or prednisolone).
- Genetic Testing Requirement: A BRCA mutation must be checked in tissue or blood before treatment starts.
- Akeega must not be taken with food. Food can cause an uncontrolled increase in abiraterone levels and serious side effects. Rule: Do not eat anything for 2 hours before and 1 hour after taking the medicine.
- If a dose is missed, it should be taken when remembered that same day, following the fasting rule. If it is time for the next day's dose, do not take a double dose to make up for it. Resume the standard schedule the next day.
Dose Modification and Management
Hematologic side effects may require dose reduction. Dosing flexibility is important because of the niraparib component.
| Toxicity | Required Action |
|---|---|
| Severe Anemia (Hb < 8 g/dL) | Interrupt treatment; resume at the next lower dose level when Hb > 9. |
| Thrombocytopenia (< 50,000) | Stop treatment; resume at a reduced dose after recovery. |
| Elevated Liver Enzymes | Monitor ALT/AST; stop treatment for elevations exceeding 5 times. |
Side Effects and Management
The combination may cause both hormonal and PARP inhibitor-related side effects:
- Anemia: The most common side effect, affecting approximately half of patients. Blood count monitoring is vital.
- Hypertension and Edema: The abiraterone component may cause high blood pressure and swollen feet. Prednisone reduces this risk.
- Fatigue: Loss of energy is common; rest and gentle exercise are recommended.
- Hypokalemia: Low potassium may occur; regular electrolyte monitoring is required.
Special Situations and Warnings
- Cardiovascular Risk: Use cautiously in patients with heart failure or serious arrhythmias.
- Bone Health: Hormone-suppressing treatment increases osteoporosis risk. Calcium and vitamin D supplementation may be needed.
- Transmission Risk: Men receiving treatment should use condoms during sexual intercourse if their partner is pregnant, because of niraparib exposure through semen.
Pharmacokinetic Properties
- Absorption: It must be taken on an empty stomach, because fatty meals may cause an uncontrolled rise in blood drug levels.
- Half-Life: Approximately 48-51 hours for niraparib and 12-15 hours for abiraterone.
- Metabolism: Metabolized by the liver (CYP3A4). It may interact with certain antibiotics and antiepileptic drugs.
References
- FDA Approval Press Release: Akeega for BRCA-positive mCRPC, August 2023.
- Chi KN, et al. Niraparib plus Abiraterone Acetate and Prednisone in mCRPC (MAGNITUDE trial). Journal of Clinical Oncology. 2023/2024 updates.
- ESMO Congress 2025: Long-term survival analysis of BRCA2-mutant mCSPC patients.
- Janssen Biotech, Akeega Prescribing Information, Updated Jan 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.